Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors
Loading...
Date
Authors
Choi, Jennifer
Anderson, Ronald
Blidner, Ada Gabriela
Cooksley, Tim
Dougan, Michael
Glezerman, Ilya
Ginex, Pamela
Girotra, Monica
Gupta, Dipti
Johnson, Douglas
Journal Title
Journal ISSN
Volume Title
Publisher
Springer
Abstract
Immune checkpoint inhibitors (ICIs) frequently result in cutaneous immune-related adverse events (IrAEs). Although the majority of these events are mild-to-moderate in severity, up to 5% are severe, which may lead to morbidity and dose interruption or discontinuation of ICI therapy. In addition, up to 25% of dermatologic IrAEs are corticosteroid-refractory or corticosteroid-dependent. These 2020 MASCC recommendations cover the diagnosis and management of cutaneous IrAEs with a focus on moderate-to-severe and corticosteroid-resistant events. Although the usage of immune-suppressive therapy has been advocated in this setting, there is a lack of randomized clinical trial data to provide a compelling level of evidence of its therapeutic benefit.
Description
Keywords
Bullous dermatoses, Corticosteroids, Cutaneous IrAEs, Inflammatory dermatitis, Pruritus, Skin rash, Vitiligo, Immune checkpoint inhibitor (ICI), Immune-related adverse events (IrAEs)
Sustainable Development Goals
Citation
Choi, J., Anderson, R., Blidner, A. et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors. Supportive Care in Cancer 28, 6119–6128 (2020). https://doi.org/10.1007/s00520-020-05706-4.